Clinical trials: Primary Lateral Sclerosis
Motor Neurone Disease, Hypoxemia and/or Hypercapnia
The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease
Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach review will be approached for participation in the…
- Trial name
- NCT03444428
- Testing
- Non Invasive Ventilation, Without Non Invasive Ventilation
- Where
- 2 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Amyotrophic Lateral Sclerosis
Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis
The purpose of this clinical trial is to asses the feasibility and the security of the intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sclerosis patients.
- Trial name
- CMN/ELA (NCT00855400)
- Testing
- Laminectomy and bone marrow stem cells transplantation, Autologous bone marrow cells collection
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Amyotrophic Lateral Sclerosis
A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a…
- Trial name
- NCT02714036
- Testing
- ibudilast
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- MediciNova
Amyotrophic Lateral Sclerosis
Spinal Cord Associative Plasticity for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen…
- Trial name
- NCT06172621
- Testing
- Spinal Cord Associative Plasticity (SCAP), Upper extremity task-oriented exercise
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Amyotrophic Lateral Sclerosis
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002.
- Trial name
- NeurALS (NCT07660614)
- Testing
- LTX-002
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 56 people
- Sponsor
- Leal Therapeutics, Inc
Amyotrophic Lateral Sclerosis
Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS
The purpose of this study is to evaluate the safety and efficacy of HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNRCS-Allo-ALS-02 inj"), through intrathecal delivery for the repeated treatment after 6 months of…
- Trial name
- NCT03214146
- Testing
- HYNRCS-Allo inj
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Hanyang University Seoul Hospital
Amyotrophic Lateral Sclerosis
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS.
- Trial name
- NCT01142856
- Testing
- autologous mesenchymal stem cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Neuromuscular Diseases
Muscle Oxygenation in Effort in Neuromuscular Diseases
Previous studies showed modifications of muscle oxygenation parameters in muscular dystrophies du to an impairment or an absence of dystrophin.
- Trial name
- OXYNEMU (NCT02789059)
- Testing
- muscle oxygenation
- Where
- 3 sites in France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Amyotrophic Lateral Sclerosis, ALS
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
- Trial name
- NCT05163886
- Testing
- LAM-002A
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IRulya Therapeutics Inc.
Amyotrophic Lateral Sclerosis
The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS.
- Trial name
- RNS60 (NCT03456882)
- Testing
- RNS60
- Where
- 23 sites in United States, Italy
- Volunteers
- 147 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels…
- Trial name
- CL201 (NCT00647296)
- Testing
- Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
A Registered Cohort Study on Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate…
- Trial name
- NCT04008329
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease.
- Trial name
- AMSC-ALS-001 (NCT03828123)
- Testing
- Suspension of human autologous MSC 3P in 1.5 ml
- Volunteers
- 26 people
- Sponsor
- Bioinova, s.r.o.
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Telemonitoring in NIV MND (OptNIVent)
This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group.
- Trial name
- OptNIVent (NCT05299372)
- Testing
- Telemonitoring via Careportal®
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
The purpose of this study is to find out if supervised exercise training using a treadmill with partial weight support is safe and has an impact on gait and function of persons with Amyotrophic lateral sclerosis.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Lou Gehrig's Disease
- Trial name
- NCT00956488
- Testing
- Treadmill Exercise
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Sporadic and Familial Amyotrophic Lateral Sclerosis
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
- Trial name
- FB1006 (NCT05923905)
- Testing
- FB1006
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral
A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells cells from adipose tissue in…
- Trial name
- NCT02290886
- Testing
- Intravenous administration of 1 million of MSC, Intravenous administration of 2 million of MSC, Intravenous administration of 4 million of MSC
- Where
- 4 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Amyotrophic Lateral Sclerosis (ALS)
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations
Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes.
- Trial name
- RAG-21-FUS-ALS (NCT07080801)
- Testing
- RAG-21
- Volunteers
- 6 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
- Trial name
- NCT02794857
- Testing
- NP001
- Where
- 22 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis, Respiratory Insufficiency
Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation
ALS is is characterized by a progressive degeneration of motor neurons, leading to progressive weakness of muscles, including respiratory muscles, the diaphragm.
- Trial name
- RespiStimALS (NCT01583088)
- Testing
- phenique nerve stimulation NeurX™ (Synapse Biomedical)
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris